Kimberly Farmer, PA
Physician Assistant · Wilmington, NCNPI 1851395198
Payments from drug & device makers
Across 130 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$261
- Pfizer$200
- Merck$193
- AbbVie$173
- E.r. Squibb & Sons, L.L.C.$172
- Lilly USA, LLC$171
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $261 |
| Pfizer | 11 | $200 |
| Merck | 12 | $193 |
| AbbVie | 9 | $173 |
| E.r. Squibb & Sons, L.L.C. | 10 | $172 |
| Lilly USA, LLC | 10 | $171 |
| GSK | 7 | $108 |
| Amgen | 6 | $99 |
| Novartis | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Bayer | 5 | $78 |
| Abbott | 3 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $78 |
| Boehringer Ingelheim | 4 | $75 |
| AstraZeneca | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Exact Sciences | 2 | $34 |
| Lundbeck LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$2,278 in reported general payments places this provider in the 80th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $55,410 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $47,820 |
| JardianceEmpagliflozin | 68 | $42,271 |
| EliquisApixaban | 52 | $38,917 |
| RybelsusSemaglutide | 14 | $26,569 |
| MyrbetriqMirabegron | 26 | $21,918 |
| BelsomraSuvorexant | 39 | $16,729 |
| TrulicityDulaglutide | 14 | $15,022 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $12,245 |
| FarxigaDapagliflozin Propanediol | 20 | $11,447 |
| VascepaIcosapent Ethyl | 31 | $10,923 |
| NexletolBempedoic Acid | 23 | $9,355 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $8,515 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,422 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $7,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $261 | $81,98066 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $108 | $56,24180 claims |
| Boehringer IngelheimJardiance, Synjardy, Stiolto Respimat | $75 | $56,15994 claims |
| PfizerEliquis | $200 | $38,91752 claims |
| MerckBelsomra, Janumet, Januvia | $193 | $28,90161 claims |
| AstraZenecaFarxiga, Brilinta | $57 | $18,28435 claims |
| Lilly USA, LLCTrulicity | $171 | $15,02214 claims |
| Esperion Therapeutics, Inc.Nexletol | $45 | $9,35523 claims |
| AbbVieLinzess, Synthroid | $173 | $8,36129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Wilmington
- Leighton MorganWilmington$21K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.